Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + Olodaterol FDC in COPD (TOnado 1)
NCT01431274Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of tiotropium + olodaterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Forced Expiratory Volume in One Second Area Under the Curve from 0 to 3 hours, Trough Forced Expiratory Volume in One Second at Day 170 and 1 more. Started Sep 2011; status: completed.
02
Drugs
tiotropium + olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01431274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431274.